Case Name: In re: OMEPRAZOLE PATENT LITIGATION Astrazeneca AB, Aktiebolaget Hassle, KBI-E, Inc., KBI, Inc., and Astrazeneca LP, Plaintiffs-Appellants, v. Mylan Laboratories, INC., Mylan Pharmaceuticals, Incorporated, Esteve Quimica, S.A., and Laboratorios Dr. Esteve, S.A., Defendants-Appellees
Court: United States Court of Appeals for the Federal Circuit
Jurisdiction: United States
Decision Date: 2008-01-22
Citations: 263 F. App'x 861
Docket Number: Nos. 2007-1476, 2007-1477, 2007-1478
Parties: In re: OMEPRAZOLE PATENT LITIGATION Astrazeneca AB, Aktiebolaget Hassle, KBI-E, Inc., KBI, Inc., and Astrazeneca LP, Plaintiffs-Appellants, v. Mylan Laboratories, INC., Mylan Pharmaceuticals, Incorporated, Esteve Quimica, S.A., and Laboratorios Dr. Esteve, S.A., Defendants-Appellees.
Judges: 
Reporter: West's Federal Appendix
Volume: 263
Pages: 861–861

Head Matter:
In re: OMEPRAZOLE PATENT LITIGATION Astrazeneca AB, Aktiebolaget Hassle, KBI-E, Inc., KBI, Inc., and Astrazeneca LP, Plaintiffs-Appellants, v. Mylan Laboratories, INC., Mylan Pharmaceuticals, Incorporated, Esteve Quimica, S.A., and Laboratorios Dr. Esteve, S.A., Defendants-Appellees.
Nos. 2007-1476, 2007-1477, 2007-1478.
United States Court of Appeals, Federal Circuit.
Jan. 22, 2008.

Opinion:
ORDER
Order Vacated, See 2008 WL 648541.
The appellant having failed to file an appendix required by Federal Circuit Rule 30(a) within the time permitted by the rules, it is
ORDERED that the notice of appeal be, and the same hereby is, DISMISSED, for failure to prosecute in accordance with the rules.